CA2284705A1 - Formulations chimiquement et thermiquement stables de norastemizole - Google Patents

Formulations chimiquement et thermiquement stables de norastemizole Download PDF

Info

Publication number
CA2284705A1
CA2284705A1 CA002284705A CA2284705A CA2284705A1 CA 2284705 A1 CA2284705 A1 CA 2284705A1 CA 002284705 A CA002284705 A CA 002284705A CA 2284705 A CA2284705 A CA 2284705A CA 2284705 A1 CA2284705 A1 CA 2284705A1
Authority
CA
Canada
Prior art keywords
norastemizole
pharmaceutically acceptable
lactose
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284705A
Other languages
English (en)
Inventor
Martin P. Redmon
Hal T. Butler
Stephen A. Wald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284705A1 publication Critical patent/CA2284705A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations chimiquement et thermiquement stables de norastémizole qui est un antihistaminique puissant. Ces compositions, ou certains de leurs sels pharmaceutiquement admis, sont exemptes de lactose, sont non hygroscopiques, sont anhydres, comprennent des grandes particules de norastémizole ou du norastémizole enrobé de façon inerte. Les composés de l'invention sont stables et faciles à fabriquer.
CA002284705A 1997-03-26 1998-03-25 Formulations chimiquement et thermiquement stables de norastemizole Abandoned CA2284705A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82447797A 1997-03-26 1997-03-26
US85178697A 1997-05-06 1997-05-06
US08/824,477 1997-05-06
US08/851,786 1997-05-06
PCT/US1998/005701 WO1998042379A2 (fr) 1997-03-26 1998-03-25 Formulations chimiquement et thermiquement stables de norastemizole

Publications (1)

Publication Number Publication Date
CA2284705A1 true CA2284705A1 (fr) 1998-10-01

Family

ID=27124816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284705A Abandoned CA2284705A1 (fr) 1997-03-26 1998-03-25 Formulations chimiquement et thermiquement stables de norastemizole

Country Status (13)

Country Link
EP (1) EP1035869A1 (fr)
JP (1) JP2002512614A (fr)
KR (1) KR20010005746A (fr)
CN (1) CN1257431A (fr)
AR (1) AR012187A1 (fr)
BR (1) BR9808428A (fr)
CA (1) CA2284705A1 (fr)
HU (1) HUP0001823A3 (fr)
NO (1) NO994655L (fr)
NZ (3) NZ517472A (fr)
RU (1) RU2214245C2 (fr)
WO (1) WO1998042379A2 (fr)
ZA (1) ZA982562B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20002567A3 (cs) 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
EP2201982A1 (fr) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
WO2011024028A1 (fr) * 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimés d'otilonium obtenus par compression directe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052544T3 (es) * 1986-02-03 1994-07-16 Janssen Pharmaceutica Nv Composiciones anti-histaminicas que contienen n-heterociclil-4-piperidinaminas.
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE257704T1 (de) * 1992-09-03 2004-01-15 Sepracor Inc Pharmazeutische zusammensetzungen enthaltend norastemizol.
WO1997019074A1 (fr) * 1995-11-17 1997-05-29 Hoechst Marion Roussel, Inc. Nouvelles (1h-benzimidazol-2-yl-amino)piperidines a substitution en position 4 utiles pour le traitement de maladies allergiques
MY116130A (en) * 1996-08-16 2003-11-28 Schering Corp Treatment of upper airway allergic responses

Also Published As

Publication number Publication date
KR20010005746A (ko) 2001-01-15
RU2214245C2 (ru) 2003-10-20
EP1035869A1 (fr) 2000-09-20
HUP0001823A2 (hu) 2001-04-28
NZ517472A (en) 2003-08-29
BR9808428A (pt) 2000-05-23
AR012187A1 (es) 2000-09-27
NZ527201A (en) 2004-12-24
NO994655L (no) 1999-11-15
NZ527200A (en) 2004-12-24
ZA982562B (en) 1998-10-01
AU735257B2 (en) 2001-07-05
HUP0001823A3 (en) 2002-04-29
WO1998042379A2 (fr) 1998-10-01
AU6868098A (en) 1998-10-20
WO1998042379A3 (fr) 2001-03-01
NO994655D0 (no) 1999-09-24
CN1257431A (zh) 2000-06-21
JP2002512614A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
US20030013740A1 (en) Stable dosage forms of fluoxetine and its enantiomers
EP0074584B1 (fr) Comprimés multi-couches à effet prolongé
US20060127473A1 (en) Compositions and methods for stabilizing active pharmaceutical ingredients
EP1058538B9 (fr) Comprime a desintegration rapide
HUP0001527A2 (hu) Laktózmentes, nem higroszkópos és vízmentes dekarboetoxiloratadin-tartalmú gyógyászati készítmények
US20150209311A1 (en) (r,r) formoterol in combination with other pharmacological agents
RU2694056C2 (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
US20020173522A1 (en) Pharmaceutical compositions comprising norastemizole
US20080293788A1 (en) Methods and Compositions for the Treatment of Pulmonary Diseases
EP1035869A1 (fr) Formulations chimiquement et thermiquement stables de norastemizole
AU735257C (en) Chemically and thermally stable norastemizole formulations
JPH1067657A (ja) マルチプルユニット型持続性製剤
CA2570386A1 (fr) Methodes d'utilisation d'albuterol et d'agents induisant l'ouverture des canaux potassiques actives par le calcium
MXPA99008710A (en) Chemically and thermally stable norastemizole formulations
CZ340699A3 (cs) Farmaceutický prostředek s obsahem norastemizolu
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
AU2011236040A1 (en) (R,R)-Formoterol in combination with other pharmacological agents
HK1027963A (en) Chemically and thermally stable norastemizole formulations
CA2570448A1 (fr) Procedes et compositions destines au traitement de maladies pulmonaires

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20060327